Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe
02:01pm, Thursday, 06'th Feb 2025
As psychedelics stocks trade higher following the release of positive data for GH Research's 5-MeO-DMT drug for treatment-resistant depression, analysts at Jefferies believe Beckley Psytech's intrana
atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout
01:30pm, Monday, 03'rd Feb 2025
Positive data from Irish biotechnology firm GH Research's Phase 2 trial of GH001, an inhalation formulation of synthetic mebufotenin (5-MeO-DMT), in treatment-resistant depression bodes well for atai
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
11:57am, Wednesday, 29'th Jan 2025
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results
atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analysts
03:30pm, Tuesday, 28'th Jan 2025
atai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for psychedelic drug candidates over the next 12 to 18 months, analysts at Jefferies believe. “S
atai Life Sciences unveils positive results from Beckley Psytech's alcohol use disorder trial
08:47am, Tuesday, 28'th Jan 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline results from Beckley Psytech's Phase 2a study of BPL-003 (intranasal 5-MeO-DMT benzoate) in alcohol use disorder. The company s
Spravato sales surged highlights commercial viability of psychedelics, analysts believe
04:22pm, Monday, 27'th Jan 2025
The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferie
atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline
08:44am, Friday, 10'th Jan 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health therapies. Dr Srinivas Rao has officially transiti
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer
atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts
11:37am, Thursday, 14'th Nov 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies
atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01
09:22am, Wednesday, 13'th Nov 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies during the third quarter of 2024. Notably, the U
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say
03:51pm, Tuesday, 12'th Nov 2024
President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented
IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
09:21am, Wednesday, 02'nd Oct 2024
MONTRÉAL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharma
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
07:00am, Wednesday, 04'th Sep 2024
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment o
Psychedelic Stock Deep Dive: Atai Life Sciences
02:00pm, Tuesday, 03'rd Sep 2024
After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure an
atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI
08:25am, Saturday, 17'th Aug 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from
